TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Survival after liver transplantation
Endpoint domain: Mortality/survival
Primary endpoint: Quality of life after liver transplantation
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Environmental contaminants 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Environmental contaminants 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hand subscale of the Stroke Impact Scale version 3.0 (SIS-Hand)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Prevalence of movement disorders in MS patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Synovial fluid analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hamilton Depression Scale (HAMD-17) scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of AESIs and SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Serum anti-SCB-2019 IgG antibody titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Count of Participants That Experienced Treatment-related Unexpected Grade 3 or Higher Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Adverse events (AEs)/Serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients with vital signs abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Attachment Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of ARDS
Endpoint domain: Adverse events/effects
Primary endpoint: Number of gout flares
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ocular Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of patients receiving an alcohol intervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Accuracy of information in the tool
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: full feed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to assigned class of medication
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Jaw symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thyroid function control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in IHTG (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in abdominal fat area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cumulative incidence of Stage 2 treatment failure
Endpoint domain: Adverse events/effects
Primary endpoint: Time to active lesion resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adapted Ideal Cardiovascular Health Score (ICH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percent Change in Score on Pain Visual Analog Scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in daily urination frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Correlation between PaO2/FiO2 and LUSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Progression-Free Survival Rate (PFSR)
Endpoint domain: Mortality/survival
Primary endpoint: Number of social determinants of cardiometabolic health identified
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Patient engagement in healthcare as measured by the Patient Activation Measure (PAM)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of strategies modified in the self-management support and education
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Irritable bowel syndrome severity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Irritable bowel syndrome quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: 28-day survival rate (%)
Endpoint domain: Mortality/survival
Primary endpoint: Patient Satisfaction score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: E-cigarette frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Motivation and contemplation to quit
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Attendance Measurement
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: relapse of depression
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulative amount of total radioactivity excreted in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative amount of total radioactivity excreted in feces
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Opevesostat Pharmacokinetics: Maximum observed concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endoscopic Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Biomarkers as indicators of sepsis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Voice Quality
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: percent change of physiological parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tidal volume distribution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Risk Detection Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Screening Tool Completion Rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Health Care Relationship Trust Scale - Revised
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of treatment-emergent and serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Study discontinuations due to adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Composite of Stroke or Systemic arterial thromboembolism
Endpoint domain: Mortality/survival
Primary endpoint: Validation of DARWEN™ AI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MiRNA146a and microRNA 223 measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence Rate of Radial Access Site Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Technical Success of Using the S.M.A.R.T. RADIANZ™ Vascular Stent System
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Rate of recurrence of hernia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Postoperative dietary energy intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in % Blood Oxygenation Level Dependent Change (%BOLD) in the Nucleus Accumbens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in % Blood Oxygenation Level Dependent Change (%BOLD) in the Dorsal Anterior Cingulate Cortex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: remission rate of chronic migraine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Implant survival at 10 years
Endpoint domain: Mortality/survival
Primary endpoint: Measured reduction in sunscreen levels in dispensers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reported use of sunscreen from surveys completed by teens
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Post-migration proportion of HIV acquisition
Endpoint domain: Mortality/survival
Primary endpoint: Child Sleep Patterns
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Parent Sleep Patterns
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: maximal tolerated dose of cabozantinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in nitric oxide (NO) metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants with Adverse Drug Reactions (ADR)
Endpoint domain: Adverse events/effects
Primary endpoint: Involuntary fixational microsaccade amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Involuntary fixational microsaccade velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Visually guided horizontal saccade amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Visually guided horizontal saccade velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Average change in minimum masking level of tinnitus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence and severity of treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (TESAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in time in target glycaemic range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pulsatile tinnitus management
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Probability of HDV relapse-free
Endpoint domain: Mortality/survival
Primary endpoint: Perception of intubation success
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient preferences
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: performance index of the Eleveld TCI model
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variation in quantity of care
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Variation in quality of care
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Variation in clinical decisions
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Caries activity assessment score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of untargeted metabolomic profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean change in the frequency of moderate to severe vasomotor symptoms from baseline to Week 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in the frequency of moderate to severe vasomotor symptoms from baseline to Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in the severity of moderate to severe vasomotor symptoms from baseline to Week 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in the severity of moderate to severe vasomotor symptoms from baseline to Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TMS Evoked Potential amplitudes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total pathologic complete response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change of flow-mediated vasodilation (FMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cerebral Regional Oxygen Saturation (cRSO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of Functional Disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change from Baseline in Non-Wound Itch by Visual Analogue Scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Wound Surface Area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Procedural Wound Pain by VAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alcohol Consumption (BAC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: usability of the online tool (System Usability Scale)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of participants with a Dose-limiting toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Score on the System Usability Scale (SUS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: rate of perioperative vulvovaginitis
Endpoint domain: Adverse events/effects
Primary endpoint: rate of wound cellulitis
Endpoint domain: Adverse events/effects
Primary endpoint: rate of incisional breakdown
Endpoint domain: Adverse events/effects
Primary endpoint: Headache frequency on weekends
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients who have ACP discussions with their treating doctor
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Proportion of patients who have ACP discussions with their caregivers
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Proportion of patients who prefer life-extending treatments
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Geometric Mean Titers (GMTs) for HPV-16 and/or HPV-18
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of participants who seroconvert to HPV-16 and/or HPV-18
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Postoperative total morphine requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum pain intraoperatively at the surgical site
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median time to completing TB diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximally tolerated dose (MTD) of Nal-IRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-exercise muscle VEGF mRNA expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-exercise serum EPO concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Plaque Index (PI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Probing Depths (PD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Clinical Attachment Level (CAL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Bleeding On Probing (BOP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anaerobic Power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Isokinetic eccentric plantarflexion torque
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Isokinetic concentric plantarflexion torque
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Isokinetic eccentric dorsiflexion torque
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Isokinetic concentric dorsiflexion torque
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: preference towards palliative telemedicine vs in person visits
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants With Cytokine Release Syndrome
Endpoint domain: Adverse events/effects
Primary endpoint: late lumen loss (LLL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: percentage root coverage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early bactericidal activity (EBA) 0-14
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in single task static postural stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in dual task postural stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in dynamic postural control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of recurrence of SBP
Endpoint domain: Mortality/survival
Primary endpoint: Duration of Response (DOR)
Endpoint domain: Physiological/clinical
Primary endpoint: Disease Control Rate (DCR)
Endpoint domain: Physiological/clinical
Primary endpoint: Number of any treatment related AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Number of irAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Time to pneumonitis
Endpoint domain: Adverse events/effects
Primary endpoint: Knee pain during cycling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean number of Heart Failure-specific hospitalizations
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Ventilatory pattern
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Spleen Volume Reduction of ≥ 35%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EQ5D-5L VAS
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Subgroup count of lymphocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of newly formed bone, soft tissue and residual biomaterial
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient reported anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Levels of Derailment
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Fatigability - Reduction in Power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Strength - 1 Repetition Maximum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Strength - Maximal Voluntary Contraction (MVC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: New antimicrobial resistance (AMR)
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma area Under the Curve (AUC(0-48hr)) for Empagliflozin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak Plasma Concentration (Cmax) of Empagliflozin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in inflammatory cell subpopulations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Abundance of liver collagen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Liver mitochondrial flux
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in PROMIS Numeric Rating Pain Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of CPP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BMI (SDS) at pubertal onset
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: General cognitive functions change from baseline/post
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Music related cognitive function change from baseline/post
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Attentional functions change from baseline/post
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Executive and spatial-cognitive abilities change from baseline/post
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Performance of PERFORM score in predicting outcome
Endpoint domain: Mortality/survival
Primary endpoint: Efficiency of intravenous regional anesthesia assessed by visual analogue scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of intravenous regional anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of intravenous regional anesthesia as regard tolerance of tourniquet pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of Cancer-Associated Fibroblasts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: rate of pulmonary expansion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Muscle function test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The thickness of the quadriceps rectus femoris and quadriceps vastus intermedius
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in ESSDAI Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vanderbilt Assessment Total Symptom Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Youth functioning Average Performance Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Sensory Integration and Praxis Test (SIPT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bruininks-Oseretsky Motor Proficiency Test-2 (BOT-2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes